Skip to content

A study to learn how safe the study treatment BAY2701250 is, how it affects the body and how it moves into, through and out of the body in healthy male participants when a single amount is given as an injection into the vein (intravenous infusion) or under the skin (subcutaneous injection).

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-503368-18-00
Acronym
20799
Enrollment
91
Registered
2023-07-21
Start date
2023-09-14
Completion date
2025-05-20
Last updated
2024-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary hypertension due to left heart disease

Interventions

None listed

Sponsors

Bayer AG
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
Male
Age
18 Years to 64 Years

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026